hVIVO plc
HVO.LDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
High Titre Influenza virus
Influenza
PrEP-001
Asthma
RSVPreF
Respiratory Syncytial Virus Infections
Experimental: Protesomal Vaccine 1 x 30 µg
Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
High Titre Influenza virus | Phase 2 | Influenza | - | - |
PrEP-001 | Phase 2 | Asthma | - | - |
RSVPreF | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Experimental: Protesomal Vaccine 1 x 30 µg | Phase 2 | Influenza | - | - |
Frequently asked questions
What is in hVIVO plc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in hVIVO plc's (HVO.L) pipeline across Phase 2. Its lead program is High Titre Influenza virus (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is hVIVO plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for hVIVO plc (HVO.L) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HVO.L biotech catalysts?→
Add HVO.L to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow hVIVO plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.